StockNews.com Ratings Highlight Brooklyn ImmunoTherapeutics’ Challenges Brooklyn ImmunoTherapeutics, a clinical-stage biotech firm, received a “hold” rating from StockNews.com. Despite its innovative therapies, the company’s financials, including a negative P/E ratio of -2.88, raise questions. Its stock performance remains volatile, with a recent high of $8.31 and a low of $6.35 over the past year.45